Drugs / ALN-AAT02
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03767829 | Dec 2018 → Jun 2020 | alpha 1-antitrypsin deficiency | Alnylam Pharmaceuticals | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2019-11-22 | Alnylam Pharmaceuticals | Results Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day alnylam.com ↗
Announces Initial Positive Clinical Results with ALN-AAT02 and ALN-HBV02 (VIR-2218), Providing Human Proof of Concept for “Enhanced Stabilization Chemistry Plus” (ESC+) GalNAc Conjugate Delivery Technology |
| 2018-10-03 | Alnylam Pharmaceuticals | Regulatory Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) alnylam.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2019-11-22 | Alnylam Pharmaceuticals | Alnylam Announces 2020 Product and Pipeline Goals and Provides Updates at R&D Day alnylam.com ↗ |
| 2018-10-03 | Alnylam Pharmaceuticals | Alnylam Submits Clinical Trial Authorization (CTA) Application for ALN-AAT02, an Investigational RNAi Therapeutic for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease (Alpha-1 Liver Disease) alnylam.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-AAT02 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03767829 ↗ |
| Route | Subcutaneous | “ALN-AAT02 will be administered subcutaneously (SC).” NCT03767829 ↗ |